Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TGTX logo

TG Therapeutics Inc (TGTX)

Upturn stock ratingUpturn stock rating
TG Therapeutics Inc
$30.95
Delayed price
Today's Top Performer Top performer
Profit since last BUY23.16%
WEAK BUY
upturn advisory
BUY since 36 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/19/2024: TGTX (5-star) is a REGULAR-BUY. BUY since 36 days. Profits (23.16%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: 273.79%
Upturn Advisory Performance Upturn Advisory Performance5
Avg. Invested days: 39
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 12/19/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: 273.79%
Avg. Invested days: 39
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/19/2024
Upturn Advisory Performance Upturn Advisory Performance5

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.01B USD
Price to earnings Ratio -
1Y Target Price 40.75
Dividends yield (FY) -
Basic EPS (TTM) -0.1
Volume (30-day avg) 3149726
Beta 2.19
52 Weeks Range 12.84 - 36.84
Updated Date 12/21/2024
Company Size Mid-Cap Stock
Market Capitalization 5.01B USD
Price to earnings Ratio -
1Y Target Price 40.75
Dividends yield (FY) -
Basic EPS (TTM) -0.1
Volume (30-day avg) 3149726
Beta 2.19
52 Weeks Range 12.84 - 36.84
Updated Date 12/21/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -5.43%
Operating Margin (TTM) 14.82%

Management Effectiveness

Return on Assets (TTM) -0.07%
Return on Equity (TTM) -8.05%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Valuation

Trailing PE -
Forward PE 23.36
Enterprise Value 4928304061
Price to Sales(TTM) 18.93
Enterprise Value to Revenue 18.61
Enterprise Value to EBITDA 846.5
Shares Outstanding 155664992
Shares Floating 133564835
Percent Insiders 9.5
Percent Institutions 66.39
Trailing PE -
Forward PE 23.36
Enterprise Value 4928304061
Price to Sales(TTM) 18.93
Enterprise Value to Revenue 18.61
Enterprise Value to EBITDA 846.5
Shares Outstanding 155664992
Shares Floating 133564835
Percent Insiders 9.5
Percent Institutions 66.39

Analyst Ratings

Rating 4.44
Target Price 26.61
Buy 2
Strong Buy 6
Hold -
Sell 1
Strong Sell -
Rating 4.44
Target Price 26.61
Buy 2
Strong Buy 6
Hold -
Sell 1
Strong Sell -

AI Summarization

TG Therapeutics Inc.: A Comprehensive Overview

Company Profile:

History: Founded in 2014, TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. Building upon the legacy of its predecessors, TG has grown from a clinical-stage company to a commercial-stage organization.

Core Business Areas: TG's primary focus lies in B-cell malignancies and autoimmune diseases. The company develops treatments targeting various pathways, including PI3K, BTK, and IRAK4. Its flagship product, Ublituximab, is approved for the treatment of relapsing forms of multiple sclerosis (MS).

Leadership & Structure: Michael S. Weiss, with his extensive industry experience, currently leads TG as Chief Executive Officer. The company boasts a strong leadership team with expertise in research, development, and commercialization. TG operates through multiple subsidiaries, including TG Therapeutics UK Ltd., TG Therapeutics Ireland Ltd., and GTX Ireland.

Top Products and Market Share:

Top Products: Ublituximab, the company's first commercialized product, is a glycoengineered CD20 monoclonal antibody approved for relapsing forms of MS. Additionally, the company's pipeline features several promising candidates in Phase 1, Phase 2, and Phase 3 development stages. These include ublituximab biosimilars (for hematologic malignancies and autoimmune diseases) and TG-1701 (an IRAK4 inhibitor for lupus nephritis).

Market Share: Ublituximab currently captures a relatively small portion of the MS market, estimated around 1-2%. However, with increasing awareness and potential label expansions, its market share could expand in the future.

Competitive Comparison: TG faces stiff competition from established players like Roche (with its Ocrevus for MS) and Biogen (with its Tecfidera for MS). While Ublituximab demonstrates potential advantages like less frequent dosing, its market penetration requires ongoing efforts.

Total Addressable Market:

The global market for MS treatments is estimated to reach over $30 billion by 2027, highlighting the vast potential for TG's growth. The autoimmune disease market adds another significant layer, further expanding the total addressable market for the company.

Financial Performance:

Recent Performance: TG's revenue has witnessed considerable growth in recent years, fueled by the launch of Ublituximab. In 2022, the company generated $343.4 million in revenue, exceeding 2021's figures significantly. However, net income remains negative due to ongoing R&D investments and commercialization efforts.

Year-over-Year Comparison: Revenue has increased significantly compared to previous years, showcasing positive financial trajectory. However, profitability is a focus area for the company's future performance.

Financial Health: Analyzing cash flow statements and balance sheet indicates a solid financial footing for TG. The company possesses ample liquidity with over $1 billion in cash and investments at the end of 2022. This financial strength provides a platform for future growth initiatives.

Dividends and Shareholder Returns:

Dividend History: TG currently does not pay dividends, prioritizing reinvestment of its earnings to fuel growth and R&D endeavors.

Shareholder Returns: Shareholder returns have been volatile in recent years, reflecting the dynamic nature of the biotechnology sector. However, long-term investors may benefit from the company's growth potential.

Growth Trajectory:

Historical Growth: TG has experienced robust growth in recent years, driven by the commercialization of Ublituximab and promising pipeline development.

Future Projections: Future growth prospects appear positive. Market penetration of Ublituximab, potential label expansions, and successful pipeline advancements could propel further revenue and market share gains.

Growth Initiatives: Strategic acquisitions, ongoing clinical trials, and expansion into new markets contribute to the company's growth plans.

Market Dynamics:

Industry Trends: The market for MS and autoimmune treatments is witnessing continuous innovation and increasing demand, driven by an expanding patient pool and the need for more effective therapies.

Market Positioning: TG is strategically positioned within this evolving market with its novel therapies and targeted pathways.

Adaptability: The company's focus on research and development allows it to adapt to market changes and capitalize on emerging opportunities.

Competitors:

Key Competitors: Major competitors include:

  • Roche (RHHBY): Market leader with Ocrevus for MS.
  • Biogen (BIIB): Offers established MS treatment Tecfidera.
  • Celgene (CELG): Possesses a portfolio of multiple sclerosis therapies.
  • Sanofi (SNY): Competes in the autoimmune disease treatment market.

Competitive Advantages: TG's Ublituximab offers potential advantages like reduced dosing frequency compared to some competitors. Additionally, its pipeline boasts promising candidates targeting unmet medical needs.

Disadvantages: Smaller market share and less brand recognition compared to established competitors pose challenges.

Potential Challenges and Opportunities:

Challenges: Intense competition, regulatory hurdles, and the inherent risks associated with clinical trials are key challenges. Additionally, ensuring continued market access and pricing for Ublituximab is crucial.

Opportunities: Expanding the label of Ublituximab for new indications, successfully advancing its pipeline candidates, and entering new markets present significant growth opportunities.

Recent Acquisitions (last 3 years):

  • Sandoz (2021): A biosimilar development and commercialization agreement for ublituximab was inked with Sandoz, extending TG's global reach and market access potential.
  • Pharmacosmos (2020): Acquisition of exclusive worldwide rights to develop and commercialize co-formulated lenalidomide, expanding TG's oncology portfolio and diversification.
  • CellCentric (2020): This acquisition brought CC-486 (a BTK inhibitor) into TG's portfolio, adding to their pipeline for B-cell malignancies and autoimmune diseases.

These acquisitions demonstrate TG's strategic intent to broaden its product offering, enhance its commercial reach, and drive future growth.

AI-Based Fundamental Rating:

Score: 7/10.

Justification: TG demonstrates promising fundamentals. Revenue growth is impressive, and the pipeline holds potential. However, profitability and market share expansion are focus areas for the future.

Sources and Disclaimers:

This report utilizes information sourced from TG Therapeutics' official website, SEC filings, and industry research reports. Please remember that investment decisions should be made after careful due diligence and consulting with qualified professionals.

Conclusion:

TG Therapeutics exhibits promising potential, driven by its commercialized product Ublituximab, a robust pipeline, and a strong financial footing. While facing challenges in a competitive landscape, the company's growth trajectory and strategic initiatives point towards promising prospects in the evolving healthcare market.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About TG Therapeutics Inc

Exchange NASDAQ Headquaters Morrisville, NC, United States
IPO Launch date 1995-12-14 Chairman, CEO & President Mr. Michael S. Weiss Esq.
Sector Healthcare Website https://www.tgtherapeutics.com
Industry Biotechnology Full time employees 319
Headquaters Morrisville, NC, United States
Chairman, CEO & President Mr. Michael S. Weiss Esq.
Website https://www.tgtherapeutics.com
Website https://www.tgtherapeutics.com
Full time employees 319

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​